ArticleCancer medicine2023

HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial.

Quchang Ouyang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.